This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings


Okay, off my soap box. When Gilead reports first-quarter earnings next Tuesday, all eyes will be on the reported Sovaldi sales. Forget about the official sell-side consensus estimate of $950 million, it's way too low based on prescription data. The more realistic consensus expectation for Sovaldi sales in the March ranges from $1.5 billion to $2 billion (encompassing patient demand and wholesaler inventory.)

Think of about that range for a moment: Sovaldi sales will exceed $1 billion in the first three months since commercial launch. There has never been a faster drug launch in history, as far as I can tell. [Yes, I know, investors are more worried about the Sovaldi tail.]

The Gilead consensus earnings estimate stands at 85 cents per share, but of course, that's too low as well given Sovaldi sales.

On the conference call, Gilead executives will be asked about Sovaldi pricing. I hope to hear a stirring defense although the company is somewhat limited in what it can say because the hepatitis C drugs deemed most competitive to Sovaldi et al (Abbive, Merck, Bristol-Myers Squibb) are not yet approved and therefore have no listed sales price. We don't know if these companies intend to price their drugs at a significant discount to Sovaldi in order to win market share.

We all know competition in hepatitis C is coming and it's likely to be intense, so maybe Gilead will use next week's call to talk about how it views hepatitis C long term and how the company intends to spend the mountain of cash it will generate in the next few years.

I stand with the FDA advisory committee of December 2012, which voted against Zohydro's approval, largely due to concerns about the abuse potential of the drug. [Zohydro is not formulated with any abuse-deterrence measures.]

The FDA should not have approved Zohydro. Instead, the agency should have told Zogenix (ZGNX) to resubmit for approval if or when the development of an abuse-resistant version of Zohydro was completed.

I understand Zogenix's point about the need for a single-entity hydrocodone product, which eliminates extended acetaminophen exposure and reduces risk of liver injury. But given the epidemic of narcotic abuse in this country, there is no excuse for introducing a product without proper safeguards.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs